MAGE-A4 T-Cell Engager Cleared for Phase 1 Trial in Solid Tumors

News
Article

CDR-Life also recently presented positive preclinical data at the November 2023 SITC Annual Meeting.

Swethajit Biswas, MD, PhD

Swethajit Biswas, MD, PhD

The FDA has cleared CDR-Life's investigational new drug application (IND) for its MAGE-A4 T-cell engager (TCE) therapy CDR404 to be evaluated in a phase 1 clinical trial in patients with solid tumors.1

“CDR404 holds the potential to become the off-the-shelf therapy for multiple cancers expressing MAGE-A4 with high unmet need, including non-small cell lung cancer (NSCLC),” Christian Leisner, PhD, Chief Executive Officer, CDR-Life, said in a statement.1 “We are thrilled to achieve this milestone and are continuing to advance several additional programs leveraging our M-gager® technology against promising intracellular cancer targets with the goal of improving patient lives.”

CDR404 is an antibody-based, bivalent and bispecific MAGE-A4 TCE developed with the use of the company’s M-gager® technology for targeting intracellular tumor antigens through the major histocompatibility complex. CDR-Life expects to initiate enrollment in the phase 1 trial in the coming months. CDR404 is the company’s lead candidate developed with the M-gager technology, which it is also using to develop 3 other therapies for undisclosed solid tumors targets: CDR505, CDR106, and CDR304.CDR-Life also has CDR101, a trispecific next-generation local activator and TCE therapy targeted BCMA, CD3, and PD-L1 for the treatment of relapsed/refractory multiple myeloma (RRMM), in lead preclinical studies.

CDR-Life recently presented promising preclinical data on CDR404 in MAGE-A4+ squamous (SQ) NSCLC at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, held November 1-5, 2023, in San Diego, California. The data were presented in 2 posters and explored MAGE-A4 expression in solid cancers and Quantitative Systems Pharmacology.2

WATCH NOW: Marcela Maus, MD, PhD, on New Questions With CAR-T's Rise in Solid Tumors

“The absence of actionable genetic alterations makes SQ-NSCLC a difficult-to-treat cancer after relapse from immune checkpoint blockade. The demonstration of high MAGE-A4 protein expression in SQ-NSCLC and potent preclinical cytotoxicity of CDR404, highlights the therapeutic promise of CDR404 in HLA-A*02:01+ patients with SQ-NSCLC. Results from the second presentation show that leveraging the QSP model for the prediction of CDR404 doses that are likely to be safe and efficacious will enable CDR-Life to select the most effective dose to carry forward into a future registrational study,” Swethajit Biswas, MD, PhD, Chief Medical Officer, CDR-Life, said in an earlier statement.2

The research found that SQ-NSCLC had the highest MAGE-A4 mRNA expression levels among solid cancers in the The Cancer Genome Atlas database, with positive immunohistochemistry in 28/50 SQ-NSCLC samples. Four different doses of CDR404 induced complete tumor regression in the in vivo SQ-NSCLC NCI-H1703 xenograft model. In another model, the QSP model predicted doses of CDR404 which might have the most favorable benefit-risk profile for patients in the upcoming phase 1 trial.2

“These milestones underscore the continued advancement of CDR404’s potential as an off-the-shelf precision immunotherapy for MAGE-A4+ solid tumors. The unique Fab-(scFv)2 molecular format and CD3 binding properties of CDR404 isvery different compared to previous T-cell engagers which have targeted MAGE-A4+ tumors, thereby optimizing the probability-of-success in the clinic,” Biswas said.2

REFERENCES
1. CDR-Life Announces FDA Clearance of IND Application for CDR404 for Treatment of Solid Tumors. News release. CDR-Life. January 23, 2024. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.cdr-life.com/wp-content/uploads/2024/01/CDR404-IND-Approval-PR.pdf
2. CDR-Life Presents Findings from Two Studies in Preparation of Phase 1 Trial with Immunotherapy CDR404 for Treatment of Solid Tumors at SITC 2023. News release. November 3, 2023. https://www.cdr-life.com/wp-content/uploads/2023/11/CDRLife_SITC-2023-Press-Release_103023.pdf
Related Videos
N. Nora Bennani, MD
David Porter, MD
Marcela Maus, MD, PhD
Thomas McCauley, PhD
Maria Pia Morelli, MD, PhD
Marcela Maus, MD, PhD,
Aliya Rashid, DO, MPH
Mazyar Shadman, MD, on Growing Research Trends in LBCL
Veit Bücklein, Dr Med, on Research Trends in Hematological Malignancy Cell Therapy
Gregory W. Roloff, MD, on Further Investigation With Sequencing and CAR T in B-ALL
© 2024 MJH Life Sciences

All rights reserved.